SG Americas Securities’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.35M | Sell |
186,662
-372,401
| -67% | -$7.04M | ﹤0.01% | 1266 |
|
|
2026
Q1 | $12.2M | Buy |
559,063
+367,692
| +192% | +$7.12M | 0.01% | 719 |
|
|
2025
Q4 | $4.12M | Sell |
191,371
-308,250
| -62% | -$6.5M | 0.01% | 1166 |
|
|
2025
Q3 | $9.63M | Buy |
499,621
+462,028
| +1,229% | +$8.24M | 0.03% | 333 |
|
|
2025
Q2 | $643K | Buy |
37,593
+28,378
| +308% | +$1.21M | ﹤0.01% | 1476 |
|
|
2025
Q1 | $588K | Buy |
9,215
+8,289
| +895% | +$873K | ﹤0.01% | 1639 |
|
|
2024
Q4 | $113K | Sell |
926
-6,267
| -87% | -$768K | ﹤0.01% | 2643 |
|
|
2024
Q3 | $898K | Sell |
7,193
-4,869
| -40% | -$673K | ﹤0.01% | 1162 |
|
|
2024
Q2 | $1.91M | Buy |
12,062
+6,943
| +136% | +$892K | 0.01% | 976 |
|
|
2024
Q1 | $663K | Buy |
+5,119
| New | +$627K | ﹤0.01% | 1304 |
|
|
2023
Q2 | – | Sell |
-14,144
| Closed | -$1.95M | – | 3104 |
|
|
2023
Q1 | $1.95M | Buy |
14,144
+6,544
| +86% | +$849K | 0.02% | 678 |
|
|
2022
Q4 | $985K | Buy |
+7,600
| New | +$881K | 0.01% | 986 |
|
|
2022
Q3 | – | Sell |
-51,064
| Closed | -$3.83M | – | 3538 |
|
|
2022
Q2 | $3.83M | Buy |
51,064
+29,396
| +136% | +$2.16M | 0.04% | 397 |
|
|
2022
Q1 | $1.69M | Buy |
+21,668
| New | +$1.66M | 0.01% | 1026 |
|
|
2021
Q4 | – | Sell |
-3,032
| Closed | -$280K | – | 3778 |
|
|
2021
Q3 | $280K | Sell |
3,032
-5,434
| -64% | -$419K | ﹤0.01% | 3001 |
|
|
2021
Q2 | $658K | Sell |
8,466
-8,552
| -50% | -$648K | ﹤0.01% | 1811 |
|
|
2021
Q1 | $1.27M | Buy |
17,018
+9,448
| +125% | +$872K | 0.01% | 1357 |
|
|
2020
Q4 | $1.29M | Sell |
7,570
-24,901
| -77% | -$3.69M | 0.01% | 1386 |
|
|
2020
Q3 | $4.56M | Buy |
32,471
+27,509
| +554% | +$4.18M | 0.03% | 380 |
|
|
2020
Q2 | $796K | Sell |
4,962
-43,303
| -90% | -$5.89M | 0.01% | 1644 |
|
|
2020
Q1 | $4.72M | Buy |
+48,265
| New | +$5.52M | 0.04% | 401 |
|
|
2019
Q4 | – | Sell |
-2,412
| Closed | -$182K | – | 3422 |
|
|
2019
Q3 | $182K | Buy |
2,412
+943
| +64% | +$111K | ﹤0.01% | 2402 |
|
|
2019
Q2 | $223K | Sell |
1,469
-4,042
| -73% | -$491K | ﹤0.01% | 2361 |
|
|
2019
Q1 | $657K | Buy |
5,511
+561
| +11% | +$72.1K | 0.01% | 1600 |
|
|
2018
Q4 | $540K | Buy |
4,950
+3,451
| +230% | +$432K | ﹤0.01% | 1816 |
|
|
2018
Q3 | $242K | Buy |
+1,499
| New | +$205K | ﹤0.01% | 2472 |
|
|
2018
Q2 | – | Sell |
-4,386
| Closed | -$325K | – | 3538 |
|
|
2018
Q1 | $325K | Buy |
4,386
+1,952
| +80% | +$130K | ﹤0.01% | 2133 |
|
|
2017
Q4 | $135K | Sell |
2,434
-5,866
| -71% | -$311K | ﹤0.01% | 2692 |
|
|
2017
Q3 | $376K | Buy |
+8,300
| New | +$332K | ﹤0.01% | 2061 |
|
|
2017
Q2 | – | Sell |
-4,706
| Closed | -$139K | – | 3496 |
|
|
2017
Q1 | $139K | Sell |
4,706
-29,169
| -86% | -$903K | ﹤0.01% | 2725 |
|
|
2016
Q4 | $929K | Buy |
33,875
+26,816
| +380% | +$1.08M | 0.01% | 1347 |
|
|
2016
Q3 | $433K | Buy |
+7,059
| New | +$213K | ﹤0.01% | 1835 |
|
|
2015
Q4 | – | Sell |
-10,036
| Closed | -$322K | – | 2968 |
|
|
2015
Q3 | $322K | Buy |
+10,036
| New | +$341K | ﹤0.01% | 1213 |
|
|
2015
Q1 | – | Sell |
-10,251
| Closed | -$148K | – | 3023 |
|
|
2014
Q4 | $148K | Buy |
+10,251
| New | +$174K | ﹤0.01% | 2651 |
|
|
2013
Q4 | – | Sell |
-19,240
| Closed | -$909K | – | 2983 |
|
|
2013
Q3 | $909K | Buy |
+19,240
| New | +$741K | ﹤0.01% | 1329 |
|
Other funds holding SRPT
EAM
SG Americas Securities's SRPT Position: Q2 2026 in Review
SG Americas Securities reduced its Sarepta Therapeutics (SRPT) stake by 67% in Q2 2026, selling an estimated $7.04M and leaving 186,662 shares worth $3.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1266.
SG Americas Securities first reported a position in SRPT in Q3 2013 and has held it in 35 quarters since. The position peaked at $12.2M in Q1 2026. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- SG Americas Securities held 186,662 shares of Sarepta Therapeutics worth $3.35M as of Q2 2026.
- SG Americas Securities sold 372,401 Sarepta Therapeutics shares in Q2 2026, an estimated $7.04M.
- Sarepta Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1266 holding.
- SG Americas Securities first reported a position in Sarepta Therapeutics in Q3 2013 and has held it in 35 quarters since.
- SG Americas Securities's Sarepta Therapeutics position peaked at $12.2M in Q1 2026.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.